Dr. Daniel Skovronsky Believes Alzheimer's Disease Treatment Breakthrough is Imminent

Health News

Dr. Daniel Skovronsky Believes Alzheimer's Disease Treatment Breakthrough is Imminent
Alzheimer's DiseaseTreatmentBreakthrough
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 86 sec. here
  • 9 min. at publisher
  • 📊 Quality Score:
  • News: 59%
  • Publisher: 97%

In this interview, Dr. Daniel Skovronsky tells MarketWatch what the market is missing about Lilly–and what might be the GLP-1 drugs of the future–as he takes a spot on the MarketWatch 50 list of the most influential people in markets.

Dr. Daniel Skovronsky believes a big leap in Alzheimer’s disease treatment may be just around the corner–and that an overlooked class of medicines could become the GLP-1 drugs of the future.

The rapid-fire innovations from Lilly and its closest competitors have stirred controversy as well as headlines. Researchers, policymakers and industry players are debating whether the benefits of next-generation Alzheimer’s treatments can justify their considerable costs and risks–and whether Medicare and employers can cover pricey new weight-loss drugs without going broke.

“This is actually my life’s work,” Skovronsky said. Lilly is now testing its experimental therapy donanemab in patients who have the pathology of Alzheimer’s in their brains but don’t yet have symptoms of the disease. Skovronsky is hopeful the drug can prevent the onset of symptoms, he said, based on the patterns seen in late-stage trials of donanemab in people who already have symptoms. “The treatment effect was the largest in the patients who had the earliest stage of disease,” he said.

Skovronsky said that donanemab’s disease-slowing effect “is really quite significant.” Nearly half the patients treated with donanemab in a clinical trial, for example, had not lost any cognition a year later, he said. For those patients to have a full year without any decline to spend with their families, he said, is “hugely impactful.”

“I think it will have the same efficacy as some of the best injectables out there,” Skovronsky said of Lilly’s experimental weight-loss pill orforglipron. With 1 billion people globally likely to benefit from the drugs, “it’s sort of inconceivable to imagine addressing the global burden of obesity with a once-a-week injectable,” he said. “It’s not something the world’s supply chains can handle, so we’re definitely going to need pills” to fight the obesity epidemic.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

MarketWatch /  🏆 3. in US

Alzheimer's Disease Treatment Breakthrough GLP-1 Drugs Eli Lilly & Co. Medical Innovation

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

U.S. stocks open higher with S&P 500 attempting longest winning streak since 2004U.S. stocks open higher with S&P 500 attempting longest winning streak since 2004Christine Idzelis is a markets reporter at MarketWatch and is based in New York.
Read more »

AMC stock plunges 19.5% after filing for ‘at the market’ sale of up to $350 million in common sharesAMC stock plunges 19.5% after filing for ‘at the market’ sale of up to $350 million in common sharesJames Rogers is a Financial Columnist for MarketWatch.
Read more »

U.S. stocks open slightly higher as S&P 500 aims for longest winning streak since 2004U.S. stocks open slightly higher as S&P 500 aims for longest winning streak since 2004Joseph Adinolfi is a markets reporter at MarketWatch.
Read more »

Blue Apron’s loss narrows more than expected but still has ‘substantial doubt’ it can continue as going concerBlue Apron’s loss narrows more than expected but still has ‘substantial doubt’ it can continue as going concerBill Peters is a Los Angeles-based MarketWatch reporter who covers earnings.
Read more »

Israel plans four-hour pauses in northern Gaza, White House saysIsrael plans four-hour pauses in northern Gaza, White House saysVictor Reklaitis is a Washington Correspondent for MarketWatch. During his time at MarketWatch, he also has served in roles in the London and New York newsrooms. Prior to joining MarketWatch, he worked at Investor’s Business Daily and for newspapers in Virginia.
Read more »

Trend tracking CTA hedge funds suffer as stock and bond markets rallyTrend tracking CTA hedge funds suffer as stock and bond markets rallyLouis Goss is a MarketWatch reporter based in London.
Read more »



Render Time: 2025-02-12 14:57:11